Actively Recruiting

Early Phase 1
Age: 18Years - 65Years
All Genders
ID07271485

Randomized, Placebo-Controlled Pilot Study of Propranolol for Treating Misophonia

Led by Bloom Mental Health, LLC · Updated on 2025-12-09

20

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating whether a single 20 mg oral dose of propranolol can temporarily reduce the emotional and physical symptoms caused by misophonia. This early phase 1 study also aims to identify factors that might predict how well participants respond to propranolol and to assess the safety and tolerability of the drug in people with misophonia. Participants will be randomly assigned to receive either a one-time 20 mg propranolol pill or a matching placebo pill. The study uses a triple-blind design to compare the effects of propranolol against placebo. Heart rate will be monitored continuously during video presentations, and participants will rate their reactions to each video clip. Grip strength will also be measured immediately after each video exposure as a secondary outcome. During the study visit, participants will undergo continuous heart rate monitoring via pulse oximetry while watching video clips designed to trigger misophonia symptoms. They will rate their responses on a visual analog scale after each clip, and grip strength will be tested to assess physical reaction. The study will monitor safety and tolerability throughout, and participation includes completing the clinical visit and assessments. The study runs until December 2026 with participants aged 18 to 65 years.

CONDITIONS

Brief Title

Propranolol for Misophonia

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18-65.
  • Able to complete study visit(s) in Littleton, CO.
  • Able to give informed consent.
  • Report clinically significant misophonia symptoms based on standardized trigger screening.
  • Score at least moderate ("2" or higher) on questions 2 and 3 of the Amsterdam Misophonia Scale at screening.
  • Able to communicate misophonic distress in writing and participate in outpatient clinical settings.
  • Agree to follow study clinician advice including seeking additional care if advised.
  • Fluent in English.
Not Eligible

You will not qualify if you...

  • Current use of scheduled propranolol for any condition.
  • Known contraindications to propranolol, including cardiogenic shock, sinus bradycardia (<50 bpm), greater than first degree heart block, blood pressure below 90/60, or asthma requiring treatment in last 5 years.
  • Other heart conditions requiring ongoing medical treatment.
  • Relative contraindications like active anorexia, purging, underweight (BMI <18.5).
  • Active drug or alcohol use within 48 hours or active drug withdrawal.
  • Untreated diabetes or endocrine disorders harmful with propranolol.
  • History of cardiovascular disease, stroke, or symptomatic blood disorders.
  • Severe physical or neurological conditions affecting participation.
  • Liver or kidney disease affected by propranolol.
  • Conditions like Raynaud disease, pheochromocytoma, psoriasis, untreated thyroid disease affected by propranolol, unexplained dizziness, low oxygen, abnormal respirations.
  • Medications interfering with propranolol effects.
  • Allergy or sensitivity to propranolol or placebo ingredients.
  • Pregnant or nursing.
  • Recent severe psychiatric conditions or hospitalization.
  • Misophonia-triggered reactions posing safety risks.
  • Misophonia better explained by other conditions like hyperacusis.
  • Severe hearing impairment interfering with triggers.
  • Triggered by control sounds like running water or car alarm.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Single day

Participants receive a one-time oral dose of either 20 mg propranolol or placebo and have their heart rate continuously monitored during video presentations. Their reactions to each video clip are measured immediately after each exposure.

1 day visit with continuous monitoring and multiple assessments

Trial Site Locations

Total: 1 location

1

Bloom Mental Health

Littleton, Colorado, United States, 80120

Actively Recruiting

Loading map...

Research Team

B

Bloom Mental Health Clinic

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here